Last $0.40 USD
Change Today +0.0049 / 1.23%
Volume 87.1K
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8 Hillside Avenue

Suite 207

Montclair, NJ 07042

United States

Phone: 973-744-1565

Fax:

FluoroPharma Medical, Inc., a biopharmaceutical company, specializes in discovering, developing, and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: CardioPET and BFPET. BFPET BFPET program has ([18F]-labeled cationic lipophilic tetraphosphonium, 18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. Its mechanism of action is to enter the myocardial cells of the heart muscle in direct proportion to blood flow and membrane potential--the most important indicators of adequate cardiac blood supply. 18-F TPP completed a Phase Ia clinical trial in 12 healthy volunteers with no adverse events and no clinically significant changes noted in follow-up clinical and laboratory testing. CardioPET CardioPET program has (Trans-9-[18F]-Fluoro-3, 4-Methyleneheptadecanoic Acid, 18-F FCPHA) as a molecular imaging agent designed to assess myocardial metabolism for patients with CAD, especially for patients who are unable to perform exercise cardiac stress-testing. In addition, 18-F TCPHA could be used for Cardiac Viability Assessment (CVA) for the prediction of improvement prior to and/or following revascularization in patients with acute CAD, including myocardial infarction, or heart attack. VasoPET The company develops VasoPET program with the lead compounds being Diadenosine-5’5’’’-P1, P4-tetraphosphate (Ap4A) analogs, such as P2, P3-monochloromethylene diadenosine 5’, 5’’’-P1, P4-tetraphosphate (Ap2CHClp2A), as a novel molecular imaging agent for the detection of ‘vulnerable’ coronary artery plaque in patients with CAD. Strategic Alliances and Commercial Agreements The company has one exclusive technology license with Massachusetts General Hospital, which consists of three of its cardiac imaging licenses. In 2012, the company entered into a clinical research services agreement with SGS Life Science Services, a company with its registered offices in Belgium, for clinical research services relating to CardioPET Phase II study to assess myocardial perfusion and fatty acid uptake in CAD patients. Intellectual Property The company has obtained the licenses to patents and patent applications from Massachusetts General Hospital, the patent assignee in each case. The issued patents covering 18-F FCPHA and 18-F TPP technologies include both composition and method of use patents within the field of diag Massachusetts General Hospital nostic cardiology that expire at various dates between December 2016 and February 2025. History FluoroPharma Medical, Inc. was founded in 2003.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FPMI:US $0.40 USD +0.0049

FPMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FPMI.
View Industry Companies
 

Industry Analysis

FPMI

Industry Average

Valuation FPMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUOROPHARMA MEDICAL INC, please visit www.fluoropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.